Company intelligence / Profile preview

SottoPelle

Scottsdale, Arizona, United States

Ownership: Private
Development stage: Other

Overview

SottoPelle's bioidentical hormone pellet therapy has been administered to over 250,000 patients worldwide and consistently reports improved patient quality of life, including better mental, physical, and sexual health, as well as reported positive effects on neurodegenerative disorders and metabolic health. There are numerous patient testimonials and clinical observations, but large-scale, placebo-controlled clinical data are not cited in public sources.

Therapeutic areas: CardiovascularEndocrinologyWomen's HealthNeurologyMen's HealthPsychiatry
Modalities: HormoneBiologic
Industry: Biotech

Beyond the preview

Go deeper on SottoPelle.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SottoPelle.

Explore the full profile